Treatment
NK Cells clinical trials
We’re tracking 152 recruiting studies that include NK Cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06732492RecruitingPhase 1
RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Wuhan, HubeiAges 3–70 - NCT06069830Recruiting
PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT04254419RecruitingPhase 1
Natural killer cell injections in the brain tumor area
This early-phase trial tests injections of lab-grown immune cells directly into (or near) a brain tumor. It aims to see if the treatment is safe and can help control recurrent, progressive, or resistant CNS tumors.
Columbus, OhioAges 1–39 - NCT05588453RecruitingPhase 1/Phase 2
Immunotherapy and temozolomide for melanoma brain metastases
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
Columbus, OhioAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT07744256RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for relapsed small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT06158828RecruitingPhase 1/Phase 2
Memory NK cells after transplant for high-risk AML
This trial tests whether adding special 'memory-like' natural killer (NK) cells to a stem cell transplant from a half-matched family donor can help treat high-risk acute myeloid leukemia (AML). It aims to make the transplant more effective against the leukemia.
St Louis, MissouriAges 18 years+ - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT04033302RecruitingPhase 1/Phase 2
Multi-CAR T cell therapy for CD7-positive blood cancers
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT06138587RecruitingPhase 1
NK cell therapy after stem cell transplant for high-risk blood cancers
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Boston, MassachusettsAges 18 years+ - NCT05995028RecruitingPhase 1
CAR-T therapy for CD7-positive blood cancers
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT05472558RecruitingPhase 1
CAR-NK cell treatment for CD19-positive relapsed lymphoma
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hanzhou, ZhejiangAges 18–75 - NCT07759856RecruitingPhase 2
Natural killer cells plus immunotherapy for small cell lung cancer
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT05272293RecruitingPhase 1/Phase 2
Immunotherapy using donor immune cells for young people with AML
This trial tests a new cancer treatment made from a close family member’s immune cells, adjusted in the lab and given to children or young adults with AML. It may help the immune system better attack leukemia, especially for high-risk, relapsed, or refractory AML.
Minsk, Minsk OblastAges 6 months–30 years
Common questions
- Are there clinical trials studying NK Cells?
- Yes. Clin2 currently lists 152 recruiting studies that include NK Cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a NK Cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is NK Cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether NK Cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.